Bill & Melinda Gates Foundation Atreca, Inc. Transaction History

Bill & Melinda Gates Foundation

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.26 - $1.12 $4,984 - $21,473	-19,173 Reduced 2.06%	912,642 $237,000
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.22 $65,792 - $91,212	-74,764 Reduced 7.43%	931,815 $913,000
Q1 2023 May 12, 2023	SELL	$0.91 - $1.82 $181,561 - $363,122	-199,518 Reduced 16.54%	1,006,579 $1.15 Million
Q4 2022 Feb 14, 2023	SELL	$0.78 - $1.68 $89,530 - $192,835	-114,783 Reduced 8.69%	1,206,097 $964,000
Q3 2022 Nov 14, 2022	SELL	$1.59 - $2.74 $16,660 - $28,709	-10,478 Reduced 0.79%	1,320,880 $2.1 Million
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $105,110 - $339,487	-65,286 Reduced 4.67%	1,331,358 $4.2 Million
Q4 2020 Feb 16, 2021	BUY	$13.03 - $17.09 $18.2 Million - $23.9 Million	1,396,644 New	1,396,644 $23 Million

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Bill & Melinda Gates Foundation, based on Form 13F filings with the SEC.

Stay updated on Bill & Melinda Gates Foundation with notifications on news.